The Role of TLRs in Anti-cancer Immunity and Tumor Rejection.

Authors :: Urban-Wojciuk Z
Khan MM
Oyler BL
Fåhraeus R
Marek-Trzonkowska N
Nita-Lazar A
Hupp TR
Goodlett DR
Source :: Frontiers in immunology [Front Immunol] 2019 Oct 22; Vol. 10, pp. 2388. Date of Electronic Publication: 2019 Oct 22 (Print Publication: 2019).
Publication Year :: 2019
Abstract: In recent years, a lot of scientific interest has focused on cancer immunotherapy. Although chronic inflammation has been described as one of the hallmarks of cancer, acute inflammation can actually trigger the immune system to fight diseases, including cancer. Toll-like receptor (TLR) ligands have long been used as adjuvants for traditional vaccines and it seems they may also play a role enhancing efficiency of tumor immunotherapy. The aim of this perspective is to discuss the effects of TLR stimulation in cancer, expression of various TLRs in different types of tumors, and finally the role of TLRs in anti-cancer immunity and tumor rejection.<br /> (Copyright © 2019 Urban-Wojciuk, Khan, Oyler, Fåhraeus, Marek-Trzonkowska, Nita-Lazar, Hupp and Goodlett.)